SHANGHAI and HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Hence then, the article about antengene announces first patient dosed in phase i attract study evaluating atg 201 cd19 cd3 tce for b cell mediated autoimmune diseases was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases )
Also on site :
- Grimes to Star in the First-Ever AI-Generated Film Coming to Theaters: Watch a Clip
- What ‘Legend of Zelda’ Superfan Jon Batiste Thinks of ‘Ocarina of Time’ Remake and the Game’s Iconic Score
- Could the US midterms further isolate Israel in Washington?